BML Investment Partners, L.P. - 31 Dec 2025 SCHEDULE 13G/A Report for ORAMED PHARMACEUTICALS INC. Common Stock par value $0.012 per share (ORMP)

Filing Manager
BML Investment Partners, L.P.
Reporting Manager
Leonard Braden Michael
Security
ORAMED PHARMACEUTICALS INC. Common Stock par value $0.012 per share
Symbol
ORMP
Shares outstanding
39,608,807 shares
Disclosed Ownership
3,287,531 shares
Ownership
8.3%
Form type
SCHEDULE 13G/A
Filing time
09 Feb 2026, 14:13:43 UTC
Date of event
31 Dec 2025
Previous filing
13 Feb 2025
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"BML Investment Partners, L.P. disclosed 8.3% ownership in ORAMED PHARMACEUTICALS INC. Common Stock par value $0.012 per share (ORMP) on 31 Dec 2025."

Quick Takeaways

  • BML Investment Partners, L.P. filed SCHEDULE 13G/A for ORAMED PHARMACEUTICALS INC. Common Stock par value $0.012 per share (ORMP).
  • Disclosed ownership: 8.3%.
  • Date of event: 31 Dec 2025.

What Changed

  • Previous schedule filing date: 13 Feb 2025.
  • Current filing was accepted on 09 Feb 2026, 14:13.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Official SEC Source

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (2)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
BML Investment Partners, L.P. 7.9% 3,167,231 0 3,167,231 Braden M Leonard BML Capital Management, LLC its General Partner By: Braden M Leonard, its Managing Member
Leonard Braden Michael 8.3% 3,287,531 120,300 3,167,231 Braden M Leonard Leonard Braden Michael

Sponsored